Abstract:Background: The prognostic value of carbohydrate antigen 19-9 (CA19-9) is known to be affected by elevated bilirubin levels in patients with gallbladder carcinoma (GBC). The clinical significance of changes in the ratio of CA19-9 levels to total bilirubin (TB) levels in patients with GBC after curative-intent resection remains unknown. The aim of this study was to determine the prognostic value of changes in preoperative and postoperative CA19-9/TB ratio in these patients. Methods: Prospectively colleced data on consecutive patients who underwent curative-intent resection for GBC between January 2015 and December 2020 stored in a multicenter database from 10 hospitals were analysed in this retrospective cohort study. Based on the adjusted CA19-9 defined as the ratio of CA19-9 to TB, and using 2×10 3 U/μmol as the upper normal value, patients were divided into a normal group (with normal preoperative and postoperative adjusted CA19-9), a normalization group (with abnormal preoperative but normal postoperative adjusted CA19-9), and a non-normalization group (with abnormal postoperative adjusted CA19-9). The primary outcomes were overall survival (OS) and recurrence-free survival (RFS). The log-rank test was used to compare OS and RFS among the groups. The Cox regression model was used to determine factors independently associated with OS and RFS. Results: The normal group (n=179 patients) and the normalization group (n=73 patients) had better OS and RFS than the non-normalization group (n=65 patients) (the 3-year OS rates 72.0%, 58.4% and 24.2%, respectively; the RFS rates 54.5%, 25.5% and 11.8%, respectively; both P <0.001). There were no significant differences between the normal and the normalization groups in OS and RFS (OS, P =0.255; RFS, P =0.130). Cox regression analysis confirmed that the non-normalization group was independently associated with worse OS and RFS. Subgroup analysis revealed that the non-normalization group of patients who received adjuvant therapy had significantly improved OS and RFS as compared to those who did not receive adjuvant therapy (OS, P =0.025; RFS, P =0.003). Conclusions: Patients with GBC who underwent curative-intent surgical resection with postoperative abnormal levels of adjusted CA19-9 (the CA19-9/TB ratio) were associated with poorer long-term survival outcomes. Adjuvant therapy after surgery improved the long-term outcomes of these patients.

The Dynamic Changes and Clinical Significance of Serum Levels of CA19-9 in Patients with Bile Duct Carcinoma

Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China.

Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA

TO ESTIMATE THE LEVELS OF CA19-9 AND ITS SIGNIFICANCE IN DIAGNOSIS AND TREATMENT OF PANCREATICOBILIARY AND GASTROINTESTINAL MALIGNANCIES

Qinical Significance of Serum Carbohydrate Antigen 19-9 Level in Gallbladder Cancer Patients

Serum CA19-9 Level is Correlated with Liver Inflammation, Cirrhosis, and Poor Prognosis after Curative Resection in Hepatitis B-related Hepatocellular Carcinoma

CEA, CA19-9 in Predicting the Clinicopathologic Characteristics and Prognosis of Primary Duodenal Carcinoma

Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.

Relationship of CA 19-9 with choledocholithiasis and cholangitis

Diagnostic Value of Elevated Serum Carbohydrate Antigen 199 Level in Acute Cholangitis Secondary to Choledocholithiasis

Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions

Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients with Resectable Pancreatic Ductal Adenocarcinoma.

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

The Clinical Value of Combined Detection of Serum Tumor Markers CEA and CA19-9 in digestive system malignancies Diagnosis

CA 19-9: Biochemical and Clinical Aspects

Elevated Serum CA19-9 Indicates Severe Liver Inflammation and Worse Survival after Curative Resection in Hepatitis B-related Hepatocellular Carcinoma.

Preoperative CA19-9: a Competitive Predictor of Recurrence in Patients with Colorectal Cancer Liver Metastases after Hepatectomy

Impact of CA19-9 in Diagnosis of Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer

Postoperative Serum CEA and CA125 Levels Are Supplementary to Perioperative CA19-9 Levels in Predicting Operative Outcomes of Pancreatic Ductal Adenocarcinoma.